Post-Doctoral Research Fellow

Fred Hutchinson Cancer Center • Seattle, WA

1d • Onsite

About The Position

Fred Hutchinson Cancer Center is an independent, nonprofit organization providing adult cancer treatment and groundbreaking research focused on cancer and infectious diseases. Based in Seattle, Fred Hutch is the only National Cancer Institute-designated cancer center in Washington. With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world’s deadliest diseases and make life beyond cancer a reality. At Fred Hutch we value collaboration, compassion, determination, excellence, innovation, integrity and respect. Our mission is directly tied to the humanity, dignity and inherent value of each employee, patient, community member and supporter. Our commitment to learning across our differences and similarities make us stronger. We seek employees who bring different and innovative ways of seeing the world and solving problems. The Lampe and Lastwika labs at Fred Hutchinson Cancer Center have a joint opening for a Post-Doctoral Research Fellow interested in translating autoantibodies produced by B lymphocytes into tumor diagnostic and therapeutic agents. Our labs integrate state-of-the-art methods from biochemistry, cellular and molecular biology, and immunology to isolate tumor-specific autoantibodies directly from cancer patients. A major focus of our joint work is to study how B cells and the autoantibodies they produce recognize and target tumor antigens. We’ve demonstrated tumor-specific autoantibodies can be excellent biomarkers of lung tumorigenesis and can be detected prior to diagnosis (see our publications in AJCCRM 2019, JNM 2022, Cancers 2023 and STM 2023, PUBMED#’s 30422669, 35483965, 37444527, 36630482). Using our unique approach of capturing autoantibodies bound to their native tumor derived epitopes ex vivo, we’ve shown tumor-specific autoantibodies target posttranslational modifications with high specificity. With this knowledge, we’ve isolated posttranslational tumor-specific B cells directly from patients. Our goal is to translate these findings into antibody-based theranostic applications. Depending on a fellow’s interests, we have projects in lung cancer early detection assays, immunoPET imaging, and antibody-based therapeutics. Most of our work is completed using highly sought cohorts of human samples and techniques including immunofluorescence microscopy, western blotting, immunohistochemistry, molecular engineering, flow cytometry and microarray piezoelectric printing.

Requirements

• A recent Ph.D. in a relevant field
• Knowledge and experience in cancer biology, biochemistry, or immunology
• Track record of productive research
• Ability to work independently and collaboratively in a team

Responsibilities

• Involved in all aspects of research, from experimental design to manuscript preparation and publication.
• Develop creative approaches to experimental design.
• Work independently and collaboratively in a team.
• Contribute to a supportive and inclusive environment.

Benefits

• medical/vision
• dental
• flexible spending accounts
• life
• disability
• retirement
• family life support
• employee assistance program
• onsite health clinic
• income-based child care subsidy
• tuition reimbursement
• paid vacation (22 days per year)
• paid sick leave (up to 30 calendar days per occurrence of a qualifying reason)
• paid holidays (13 days per year)
• paid parental leave (up to 4 weeks)

What This Job Offers

• Job Type: Full-time
• Career Level: Entry Level
• Education Level: Ph.D. or professional degree